Reported Sunday, Natera Will Unveil SAGITTARIUS Phase III Data At ESMO 2026 Showing Signatera Results Changed Treatment Plans For One In Three Colon Cancer Patients, Of Which 87% De-Escalated On MRD Negativity
Share
Why It Matters
Natera is sharing new research showing their cancer blood test helped doctors change treatment plans. One in three colon cancer patients got less intense treatment after testing negative.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.